fashion -WSS

fashion

author：leisure time 2025-09-30 20:17:50 - browse：252

Treeline Northwest — AP Photo/Ted S. Warren

Josh Bilenker’s last company, Loxo Oncology, was purchased by Eli Lilly for $8 billion. No surprise, then, that his next effort has already raised at least $473 million in funding from private investors even before telling the public what, exactly, it is working on.

Treeline Biosciences, the new venture by Bilenker and Jeffrey Engelman, formerly Novartis’s top cancer researcher, has hired more than 130 people across three research sites in little more than a year, according to a company blog post, regulatory filings, and STAT reporting.

Treeline’s website doesn’t mention a single drug target or disease. In a paper published last year in Nature Cancer, Engelman and several colleagues reviewed the history of a class of cancer drugs called PI3 kinase inhibitors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： AstraZeneca stays mum on Medicare drug pricing negotiations

entertainment

WSS

6 phony surgeries that take placebo to the extreme

In utero gene editing: an explainer

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

He's a Nobel laureate. Critics say he was misleading on Covid

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Wikipedia

fashion

Wikipedia

In Memoriam: Notable people who died in 2023

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Continuity nursing helped my family in our darkest PICU moments

New documents shed light on MD Anderson Cancer Institute feud

How one medical school became remarkably diverse

Why CTE doesn’t keep Americans from enjoying the Super Bowl

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

With competition flaring, obesity drug hits goal in liver disease study

Virginia high school admissions case could be legal follow

The CDC's new social media misinformation war

focus

What’s missing from the debate over nursing home staff minimums

Unique patient identifier: Experts argue the benefits, pitfalls

Top private equity targets in 2023: cardiology, clinical trials, lasers

The CDC's new social media misinformation war

A protest over insulin prices is seen as a fight for life

Cano Health’s bankruptcy is a warning for Medicare Advantage

focus

entertainment

leisure time

explore